Key Stats for Novo Nordisk Stock
- Price change for Novo Nordisk stock: -9%
- $NVO Stock Price as of Jul. 31: $47
- 52-Week High: $64
- $NVO Stock Price Target: $48
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Novo Nordisk (NVO) stock dropped sharply on Friday, falling as much as 10% at one point, after the company announced that its experimental heart drug ziltivekimab failed to hit its main goal in a late-stage trial.
The drug did not significantly reduce major adverse cardiovascular events, known as MACE, compared to placebo. MACE includes cardiovascular death, non-fatal heart attack, and non-fatal stroke.
- The trial tested more than 6,300 patients who had atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammation.
- Ziltivekimab works by blocking the IL-6 inflammatory pathway.
- While the drug showed some biological effect, that didn’t translate into a statistically meaningful reduction in cardiovascular events.
- Serious infections were more common in patients taking the drug, though overall adverse event rates and mortality were similar between groups.
Chief Scientific Officer Martin Holst Lange said the company remains committed to cardiovascular disease research despite the setback.
But analysts see this as more than just a single failed trial. Jefferies called the result “strategically negative,” noting it removes one of Novo’s more credible growth opportunities outside of obesity and reinforces how dependent the company has become on commercial execution in obesity and sourcing outside innovation for future growth.
Interestingly, both Jefferies and Citi analysts noted the stock’s drop seemed larger than ziltivekimab’s actual contribution to Novo’s overall business would justify.
This is the second major clinical setback for Novo Nordisk stock this year. Back in February, shares tumbled after disappointing head-to-head results for CagriSema, the company’s next-generation weight-loss drug, against a rival treatment from Eli Lilly. If Friday’s losses hold, Novo Nordisk stock will turn negative for the year.
The timing stings because investor sentiment had been cautiously improving.
Novo successfully launched the Wegovy pill in the U.S. in January, the first oral GLP-1 treatment for weight loss, and later expanded that launch to the UAE and UK over the summer. Eli Lilly launched a competing pill, Foundayo, in April, though it has seen slower uptake so far.
Even with that pill momentum, Novo Nordisk stock remains under pressure because pill pricing tends to be lower, and it still represents just a fraction of total company sales. Novo also continues to face intense competition from Eli Lilly’s GLP-1 products, which have been rapidly gaining market share.
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free) >>>
What the Market Is Telling Us About Novo Nordisk Stock
A near-double-digit drop on one failed trial shows just how sensitive Novo Nordisk stock has become to pipeline news.
With obesity competition intensifying and pricing pressure building, investors have been leaning on Novo’s broader pipeline, including cardiovascular programs like ziltivekimab, as proof the company can diversify beyond its core weight-loss and diabetes franchise.
Losing that story hurts confidence even if the direct financial impact is small.
Novo reports Q2 earnings next week, which should give investors a clearer picture of how the broader obesity market, including pill uptake and competitive dynamics with Eli Lilly, is actually shaping up heading into the back half of the year.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Novo Nordisk Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
